Fri, Nov 28, 2014, 2:39 PM EST - U.S. Markets closed early today


% | $
Quotes you view appear here for quick access.

Cytosorbents Corporation Message Board

  • jaxla jaxla Sep 10, 2013 6:05 PM Flag

    What are we missing here???

    I have never seen such a promising company issuing so much GOOD news and yet the stock price is "stuck in the mud". Just not making any sense. I agree with oboeman, if we have another bad quarter of sales, we have a problem that is not being discussed.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • moto1960 Sep 11, 2013 10:07 AM Flag

      What are we missing. . . Money! From a start up business standpoint, CTSO needs cash to advance their business. They need money for salaries, product development and manufacturing, various meetings with other possible alliances, and all of the other requirements needed to run a business. In most cases, revenue is derived from sales. Well, look at the revenue and compare that with the cost of running a business and you'll realize that something has to give. In this case, it's the authorized share count. LPC along with a possible larger investor, seem to have agreed to buy CTSO on the open market at around a dime.
      This is a medical device company, not a candy store. Lives could be in the balance in the future with our products, and the powers that be (FDA), needs to know that our products do what they claim, before they become the new standard on the market. Remember the C.C. , remember those names and their credentials? Those individuals have to be compensated. They are given shares, I'm sure, but they also need salaries for their livelihood. The authorized share count is high, so until we see a balance in income to debt, a financial partner, or a buyout, we' ll be here at $.10 for a while (excluding a R/S). JMO, MDLAND~

    • we have already had another bad quarter of sales, and another, and another, and another going back to when most here thought the "roll out" (18 months ago) which had been preceded by a $500k inventory build (two years ago) meant sales were going to begin, and begin with a burst.
      instead chan is still talking about studies which are intended to help in the design of yet more studies -- which is what he was saying after the CE mark 2 1/2 years ago.
      do you notice a pattern?

    • What is the good news? It's all fluff, that is the problem.

      The price will go up when one or more of these things happen:
      1) PRODUCT Sales increase materially and the trend is sustained over several quarters
      2) Trial results (not preliminary) are released and efficacy is clearly established
      3) Deep-pocketed partner is announced

      Until you see these things, they can release 50 PRs with $200k grants and it won't mean a thing.

      • 2 Replies to ctso4life
      • And BTW, the pumpers on this board will surely flock to this and tell you otherwise, but the market is telling you that I am right.

        The shrill cries of "predatory short selling" and shady parties keeping the price down are the result of denial and paranoia. The stock is where it is because the company, thus far, has failed to deliver anything substantive to the street.

        P.S. Zacks does not count as "the street" as anyone at a real investment bank/research firm will immediately tell you.

      • Totally agree. A partner is the next potential catalyst. Do not expect phenomenal sales, the company is not at that stage yet. Trial results will not be until next year so accumulate if you believe in the technology. No question this is speculative and no question the results to the dosing trial will be binary in nature. If these results show efficacy, you can count on an FDA trial initiation within 3 months of the results. If negative, forget that catalyst or anything else. . KOL adoption is fine. Anecdotal case studies are fine. They create interest and small funding support from various agencies. However, as the ctsp4life so succinctly and eloquently surmised.......Validation, partnerships, positive results and most importantly, SALES will drive the pps. GLTA

0.202-0.004(-1.75%)Nov 28 12:58 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.